Aurobindo Pharma Limited (BOM:524804)

Aurobindo Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Revenue	349,671	336,531	317,237	290,019	248,554	234,555
Other Revenue	-318.4	-	-	-	-	-
Revenue	349,353	336,531	317,237	290,019	248,554	234,555
Revenue Growth	9.09%	6.08%	9.38%	16.68%	5.97%	-5.33%
Cost of Revenue	143,752	139,875	134,839	129,857	116,417	104,499
Gross Profit	205,601	196,656	182,399	160,162	132,137	130,056
Selling, General & Admin	54,981	52,468	45,470	40,434	36,560	35,751
Other Operating Expenses	78,723	75,068	70,603	60,894	58,083	49,976
Operating Expenses	152,122	145,142	131,985	116,247	107,018	96,992
Operating Income	53,479	51,514	50,414	43,915	25,119	33,064
Interest Expense	-3,562	-3,523	-4,404	-2,681	-1,290	-368.4
Interest & Investment Income	3,314	3,314	3,564	2,883	1,485	349.7
Earnings From Equity Investments	-19.4	15.2	-316.9	-171.6	-116.7	-312.5
Currency Exchange Gain (Loss)	429.4	-100.7	-226.5	387.8	-	699.6
Other Non Operating Income (Expenses)	2,299	1,236	1,962	1,672	974.6	1,028
EBT Excluding Unusual Items	55,939	52,455	50,992	46,006	26,173	34,461
Merger & Restructuring Charges	-401.8	-	-	-986.6	-	-
Impairment of Goodwill	-	-	-96.2	-27.4	-70.3	-
Gain (Loss) on Sale of Investments	14.2	14.2	335.3	1	-	290.8
Gain (Loss) on Sale of Assets	-243	-243	-89.4	234.9	132.3	-400.2
Asset Writedown	-493	-493	-600.2	-2,834	-239.6	-1,922
Other Unusual Items	-614.4	-614.4	121.3	1,407	130.1	1,298
Pretax Income	54,201	51,119	50,663	43,800	26,125	33,727
Income Tax Expense	17,093	16,089	15,827	12,110	6,849	7,256
Earnings From Continuing Operations	37,108	35,030	34,836	31,690	19,277	26,471
Minority Interest in Earnings	17.6	17.8	23.1	40	-1.5	10.4
Net Income	37,126	35,048	34,859	31,730	19,275	26,482
Net Income to Common	37,126	35,048	34,859	31,730	19,275	26,482
Net Income Growth	9.47%	0.54%	9.86%	64.62%	-27.21%	-50.36%
Shares Outstanding (Basic)	580	581	583	586	586	586
Shares Outstanding (Diluted)	580	581	583	586	586	586
Shares Change	-0.25%	-0.36%	-0.52%	-	-	-
EPS (Basic)	63.99	60.34	59.81	54.15	32.90	45.20
EPS (Diluted)	63.99	60.34	59.81	54.15	32.90	45.19
EPS Growth	9.73%	0.89%	10.44%	64.62%	-27.21%	-50.37%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	-	28,406	19,568	-3,458	-170.5	29,636
Free Cash Flow Per Share	-	48.91	33.57	-5.90	-0.29	50.58
Dividend Per Share	-	-	-	4.500	3.000	9.000
Dividend Growth	-	-	-	50.00%	-66.67%	125.00%
Gross Margin	58.85%	58.44%	57.50%	55.23%	53.16%	55.45%
Operating Margin	15.31%	15.31%	15.89%	15.14%	10.11%	14.10%
Profit Margin	10.63%	10.41%	10.99%	10.94%	7.75%	11.29%
Free Cash Flow Margin	-	8.44%	6.17%	-1.19%	-0.07%	12.63%
EBITDA	70,208	67,796	64,906	57,641	36,344	43,114
EBITDA Margin	20.10%	20.14%	20.46%	19.88%	14.62%	18.38%
D&A For EBITDA	16,729	16,282	14,492	13,726	11,225	10,050
EBIT	53,479	51,514	50,414	43,915	25,119	33,064
EBIT Margin	15.31%	15.31%	15.89%	15.14%	10.11%	14.10%
Effective Tax Rate	31.54%	31.47%	31.24%	27.65%	26.21%	21.52%
Revenue as Reported	355,863	341,452	323,456	295,593	251,460	237,758

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 22, 2026

Data Sources Report a data error